INDSWFTLABPharmaceuticals
Ind Swift Laboratories Ltd — Cash Flow Statement
₹131.43
+0.97%
Ind Swift Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Free Cash Flow | -207.63 Cr | 181.85 Cr | 131.86 Cr | 130.55 Cr |
| Repayment Of Debt | -37.43 Cr | -45.91 Cr | -36.01 Cr | -39.85 Cr |
| Capital Expenditure | -44.52 Cr | -12.77 Cr | -18.41 Cr | -4.40 Cr |
| End Cash Position | 431.48 Cr | 17.07 Cr | 25.77 Cr | 11.61 Cr |
| Other Cash Adjustment Outside Changein Cash | -18.20 Cr | — | — | 1000.00 |
| Beginning Cash Position | 18.20 Cr | 21.48 Cr | 11.60 Cr | 10.58 Cr |
| Changes In Cash | 431.48 Cr | -4.41 Cr | 14.17 Cr | 1.03 Cr |
| Financing Cash Flow | 698.91 Cr | -185.66 Cr | -140.88 Cr | -123.75 Cr |
| Net Other Financing Charges | 862.39 Cr | -11.23 Cr | — | — |
| Interest Paid Cff | -126.05 Cr | -128.52 Cr | -104.87 Cr | -83.89 Cr |
| Net Issuance Payments Of Debt | -37.43 Cr | -45.91 Cr | -36.01 Cr | -39.85 Cr |
| Net Long Term Debt Issuance | -37.43 Cr | -45.91 Cr | -36.01 Cr | -39.85 Cr |
| Long Term Debt Payments | -37.43 Cr | -45.91 Cr | -36.01 Cr | -39.85 Cr |
| Investing Cash Flow | -104.32 Cr | -13.37 Cr | 4.77 Cr | -10.17 Cr |
| Net Other Investing Changes | 1000.00 | 1000.00 | — | — |
| Interest Received Cfi | 18.37 Cr | 0.53 Cr | 0.56 Cr | 0.51 Cr |
| Net Investment Purchase And Sale | -81.12 Cr | -1.27 Cr | 17.13 Cr | -6.29 Cr |
| Net PPE Purchase And Sale | -41.57 Cr | -12.63 Cr | -12.92 Cr | -3.91 Cr |
| Sale Of PPE | 2.95 Cr | 0.14 Cr | 5.50 Cr | 0.00 |
| Purchase Of PPE | -44.52 Cr | -12.77 Cr | -18.41 Cr | -3.91 Cr |
| Operating Cash Flow | -163.12 Cr | 194.62 Cr | 150.27 Cr | 134.95 Cr |
| Change In Working Capital | -483.05 Cr | -51.33 Cr | -87.92 Cr | -62.41 Cr |
| Change In Other Current Liabilities | 32.84 Cr | 17.07 Cr | 31.68 Cr | 13.10 Cr |
| Change In Other Current Assets | -436.53 Cr | -21.61 Cr | -40.59 Cr | -4.20 Cr |
| Change In Inventory | 32.89 Cr | -10.10 Cr | -52.83 Cr | -32.85 Cr |
| Change In Receivables | -112.24 Cr | -36.68 Cr | -26.18 Cr | -38.45 Cr |
| Other Non Cash Items | 26.72 Cr | 77.63 Cr | 87.95 Cr | 90.23 Cr |
| Provisionand Write Offof Assets | 24.77 Cr | 0.00 | 0.00 | 0.00 |
| Deferred Tax | -0.06 Cr | -0.22 Cr | -0.09 Cr | 0.00 |
| Depreciation And Amortization | 53.30 Cr | 57.36 Cr | 131.04 Cr | 87.29 Cr |
| Depreciation | 53.30 Cr | 57.36 Cr | 131.04 Cr | 87.29 Cr |
| Net Foreign Currency Exchange Gain Loss | -2.50 Cr | -3.07 Cr | 3.75 Cr | 1.83 Cr |
| Gain Loss On Sale Of PPE | 22.53 Cr | 1.06 Cr | 13.67 Cr | 0.00 |
| Net Income From Continuing Operations | 195.17 Cr | 113.17 Cr | 12.53 Cr | 18.01 Cr |
| Gain Loss On Sale Of Business | — | 0.00 | -10.66 Cr | 0.00 |
| Issuance Of Debt | — | — | 0.00 | 0.00 |
| Long Term Debt Issuance | — | — | 0.00 | 0.00 |
| Net Intangibles Purchase And Sale | — | — | 0.00 | -0.49 Cr |
| Purchase Of Intangibles | — | — | 0.00 | -0.49 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ind Swift Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.